•  
  •  
  •  
  •  

2026-08-06 05:21:59

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  EIR

Stock Report

  • Zydus Lifesciences Ltd receives EIR from the USFDA for its injectable facility with VAI classification
  • Ajanta Pharma Ltd receives EIR from USFDA for Paithan facility
  • Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification
  • Granules Pharmaceuticals, Inc. Receives USFDA EIR for Chantilly Facility
  • Lupin's Ankleshwar Facility Receives EIR from U.S. FDA
  • Supriya Lifescience Receives USFDA EIR with VAI Classification for Maharashtra API Facility
  • Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Granules India's Packaging Facility in US gets FDA EIR with No Action Indicated Status
  • Lupin Receives EIR from US FDA for its Goa Facility
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Lupin receives EIR from US FDA for its Nagpur Injectable Facility
  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
  • Zydus receives EIR for the injectable facility located at Jarod
  • Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
  • Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for facility at Panelav
  • SMS Pharmaceuticals Ltd receives EIR from USFDA for Central Laboratory Analytical Services
  • Unichem Laboratories Ltd receives EIR from USFDA classifying Roha API facility as VAI
  • SMS Lifesciences India Ltd receives EIR with VAI status from USFDA for API facility at Kazipally
  • EIR from USFDA, for Shilpa Medicare Ltd. Unit VI, Bengaluru.
  • Neuland Laboratories Ltd receives EIR from USFDA for Unit 2 at Pashamylaram Village
  • Concord Biotech Limited receives EIR from USFDA for API facility at Dholka
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for API-III facility at Karakhadi

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025